A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma.

Trial Profile

A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Bosutinib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2012 Actual patient number is 3 as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 May 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top